长按二维码,关注官方公众号
You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
Cell and gene therapy has shown an unprecedented prosperity with the continuous iteration and development of technology, but the domestic cutting-edge therapies are still in the early stage. In recent years, the regulatory authorities, as a strong backing for the development of CGT industry, have published consultation drafts and guidelines, giving great support and encouragement to the development of cutting-edge technologies such as CGT. However,
What are the latest regulatory policies and requirements for the application, technical evaluation, and ethical genetic resources of cutting-edge therapies?
How to evaluate the non-clinical pharmacology and toxicology, CMC of CGT products? How to choose experimental animal models and their substitutes ?
How to advance clinical development to meet the requirements of IIT/IND filing? How to conduct a dose escalation trial and design for a first-in-human clinical trial?
What breakthroughs and convergences will occur in the process of developing and translating different delivery vectors (AAV and other viruses, nanoparticles LNP-mRNA, exosomes, etc.), gene editing, Allogeneic Cell Therapy, iPSCs, regenerative medicine, and other cutting-edge technologies ? How to deal with the challenges of CMC and industrialization?
What other cellular immunotherapy and combination therapies can effectively address the challenges of treating solid tumors? How is the preclinical and clinical progress?
IGC is the first regional congress focusing on CGT from bench to bedside. This year, IGC will continually discuss the leading breakthroughs of new researches, new technologies and new products of In Vivo Genome Editing Therapy, Viral and Non-viral Vector Gene Therapy, Stem Cell Gene Therapy, Allogeneic Cell Therapy, Cellular Immunotherapy and Combo for Solid Tumors, iPSCs and MSCs at home and abroad from the perspective of 4 forums and 14 sessions. Last year, it has attracted 1000+ participants, including industry, academia, research, clinic and so on. This year, it will continue to gather 1200+ senior R&D executives and scientists from leading players in the immunotherapy and CGT sector, discussing the most cutting-edge technologies and research findings worldwide applicable across the region.
IGC is committed to establishing an international industry-academia-research platform for immunotherapy, cell and gene therapy. The previous 5 congresses were respectively successfully held in Wuhan and Beijing, attracting 4000+ people from industry, academia, research, clinical studies and investment. IGC accumulatively invited 320+ well-known experts and scholars at home and abroad, and R&D scientists from leading enterprise as honorable speakers, to accelerate the industrial application of immunotherapy, cell therapy and gene therapy.
